Theravance Biopharma (TBPH)
(Real Time Quote from BATS)
$8.29 USD
-0.05 (-0.60%)
Updated May 28, 2024 09:42 AM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TBPH 8.29 -0.05(-0.60%)
Will TBPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Other News for TBPH
Theravance Biopharma (TBPH) Receives a Hold from TD Cowen
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)
Tracking Seth Klarman's Baupost Group Holdings - Q1 2024 Update
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects